ORDER A TEST Log In Contact Us
Hero Background

LIFE SCIENCES

Discover, design, and deliver the right drug for the right patient

Tempus provides integrated solutions to help meet your needs from early discovery through commercialization.

CONTACT US

Our Solutions

  1. Sequencing

    Use our genomic platform to prospectively sequence through clinical trials and retrospectively support research priorities.
  2. Data Collaborations

    Leverage real-world datasets of matched molecular and clinical data with digital whole slide pathology images to uncover new insights across the research and development spectrum.
  3. Biological Modeling

    Leverage our robust biobank of patient-derived tumor organoids to accelerate drug discovery.

  4. Companion Diagnostics

    Integrate CDx claims into Tempus assays through a validated and established sequencing platform to pursue companion diagnostic biomarkers.
  5. Multi-omics

    Discover unique molecular targets, track methylation patterns, and build multimodal datasets with our robust suite of high throughput multi-omic solutions.

  6. Clinical Research Organization Services

    Bring discoveries from the lab to market through our full-service CRO.
  7. Clinical Trial Enrollment

    Utilize NGS and EMR integrations to identify patients that match your study's eligibility criteria, including targetable biomarkers from DNA and RNA.
  8. Tempus Studies

    Leverage our end to end solutions to design and execute Tempus-sponsored clinical trials for therapeutics, devices, and diagnostics from study concept to registrational filing.
  9. Care Gap Solution

    Timely AI-enabled notifications to accelerate adoption of precision care pathways and avoid gaps in care.

We partner with scientists and researchers to accelerate the drug development process

  • 95%

    of the top 20 pharma oncology companies partner with Tempus

  • 200+

    biopharma partnerships

image description

Mirati Therapeutics

Make quicker decisions by simulating and contextualizing data with Tempus

Read case study

AstraZeneca

Learn how AstraZeneca integrated Tempus data and tools across their Oncology R&D governance process.

Read case study

AstraZeneca

Enhance data-driven R&D strategy

Read press release

GSK

Leveraging diagnostics and data to drive next-generation drug development

Watch webinar

Kronos Bio

Advance current clinical candidate markers

Read press release

Eli Lilly

Increasing accessibility to testing

Read press release

GSK

Intersection of genomics and machine learning

Read press release

AstraZeneca

Increasing Probability of Technical Success (PTS)

Read blog

Janssen

Using RWD

Read article

AstraZeneca and Pfizer

Data-driven CDx development

Read article

TScan

RWD and immuno-oncology

Read article

GSK

Using data and AI/ML to achieve precision medicine

Read article

AstraZeneca

Multimodal data for Probability of Technical Success (PTS)

Watch webinar

Eisai

The evolution of RWE and HEOR

Read article

Sermonix

Trial enrollment acceleration

Read case study

Gilead

RWD and decision making

Read article

TScan

Partner to develop assays

Read press release

AstraZeneca

Clinical trials for novel therapies

Read press release

Actuate Therapeutics

Use liquid biopsy and RUO DNA Methylation to discover and validate

Read press release

Genmab

Discover new targets

Read press release

Janssen

Leveraging AI/ML for RWD

Read press release

AstraZeneca

Strategic collaboration

Read press release

Bristol Myers Squibb

Discover RNA based targets

Read press release

Gilead

Biomarker innovation

Watch webinar

Kronos Bio

RWE for drug development

Read article

Sermonix

Patient recruitment

Read article

Geisinger

AI and ECG

Read blog

Genmab

Multimodal RWD

Read article

Aadi Bioscience

Accelerate trial enrollment

Read case study

A2 Bio

NGS to power R&D

Read article

Kronos Bio

Collaboration around data and organoids

Read press release

Kartos Therapeutics

Progressing the goal of innovative therapies

Read press release

Recursion

Advance biomarker-driven therapeutic development with a data-first approach

Read press release

Bristol Myers Squibb

Identify new targets and validate them faster and with higher confidence

Read press release

Kronos Bio

Impact of multimodal data in translational science

Watch webinar

Data Collaborations

  • ~6M

    de-identified research records to power scientific discovery to improve patient outcomes

  • 900K+

    records with matched clinical data linked with genomic information

  • 200K+

    records with whole transcriptome profiles

image description

Sequencing

  • 9

    NGS tests for clinical trial and research sequencing

  • 6.5K+

    oncologists rely on Tempus as their precision medicine partner

image description

Clinical Trial Solutions

  • ~10

    business days for just-in-time trial activation

  • 90+

    health systems representing 500+ sites

  • 30K+

    patients have been identified for potential enrollment into clinical trials in our network

image description
Our Impact

Thanks to Tempus, we are able to identify patients that can be helped with our proprietary TMod™ platform. Without them, we wouldn’t be able to do this.

William Go, SVP, Head of Development at A2 Biotherapeutics (TMod™ is a trademark of A2 Biotherapeutics)

Our Impact

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

Learn more about our partnership with Genmab
Our Impact

Bayer’s strong focus in precision medicine combined with Tempus’ unique testing offering has culminated in this collaboration to bring genomic testing to cancer patients.

Bhavesh Ashar, Senior Vice President, Head of U.S. Oncology at Bayer

Learn more about our partnership with Bayer
Our Impact

Our partnership with Tempus will enable us to collect important retrospective information about the patients enrolled in the dose escalation part of our clinical trial that we can potentially use to inform enrollment in the expansion stage of our study.

Jorge DiMartino, Chief Medical Officer and Executive Vice President, Clinical Development at Kronos Bio

Learn more about our partnership with Kronos

Featured Resources

View all RESOURCES
  • UPCOMING WEBINAR:

    Q&A: Increasing diverse patient enrollment and accrual in oncology clinical trials

    Oncologists from The Oncology Institute of Hope and Innovation (TOI) discuss strategies for how they achieve non-white ethnicity patient enrollment in their clinical trial portfolio.

    Read more
  • UPCOMING WEBINAR:

    Unlocking the power of RNA in drug development

    Hear insights from industry leaders on understanding, leveraging, and validating RNA in the drug development process.

    Watch replay
  • UPCOMING WEBINAR:

    Streamlining clinical trial operational overhead at a multi-location, community-based cancer care center

    The Oncology Institute of Hope and Innovation (TOI) highlights how the Tempus TIME program amplified the ability to identify the right patient for the right study at the right time, while reducing the time and resources needed to open new clinical trials.

    Read more
  • UPCOMING WEBINAR:

    Impact of multimodal data in translational science

    In this panel session we spoke to Translational Scientists who have been utilizing multi-modal insights in their daily work and discussed what new information can come to light by utilizing these tools.

    Watch replay
  • UPCOMING WEBINAR:

    Tempus’ FDA approval and insights on the use of companion diagnostics in clinical development

    In this webinar, you will hear how the Tempus platform can support development of new therapies by combining real-world data, next-generation sequencing, and artificial-intelligence to advance precision oncology. Our regulatory and scientific experts will provide an overview of the pathways for diagnostics and share best practices for biopharma and biotech sponsors to consider in clinical trial design and the development of companion diagnostics.

    Watch replay
  • UPCOMING WEBINAR:

    The value of RNA sequencing in drug discovery

    Learn the value of RNA Sequencing in identifying altered expression programs in tumors that are measurable by RNA-Seq but not DNA-Seq.

    Read more
  • UPCOMING WEBINAR:

    Industry Expert Theater Presentation* from the 2023 ASCO® Annual Meeting

    Hear from Drs. Ezra Cohen, Kate Sasser and Calvin Chao from Tempus as they explore the intersection of real world data, machine learning, and genomic sequencing to revolutionize patient care. They discuss Tempus’ suite of technologies and NGS platform which work together to rapidly deliver insights that are transforming precision oncology from clinical development to the oncology practice.

    Watch now
  • UPCOMING WEBINAR:

    Precision medicine made real: enhancing genetic testing with AI algorithms

    Genetic testing has been a breakthrough in clinical research and patient profiling, allowing providers to pinpoint the precise factors in a person’s genome that may affect their health or response to treatments.

    Read more
  • UPCOMING WEBINAR:

    Leveraging Tempus AI and multimodal data to increase probability of technical success in Biopharma

    Advances in oncology treatments over the past 20 years have significantly extended patients’ life expectancy.

    Read more

Tempus empowers you to make smarter, faster, and more efficient decisions

Get customized solutions for your needs.